Rare Disease Show Episode 19: Decoding Pulmonary Arterial Hypertension with Dr Brajesh Kumar Mishra
Written By : Dr. Nandita Mohan
Published On 2024-11-12 15:45 GMT | Update On 2024-11-12 15:45 GMT
Advertisement
Medical Dialogues presents a rare disease series, delving into the realm of uncommon medical conditions. Rare diseases are medical conditions that affect only a small percentage of the population. Throughout this series, we'll discuss these rare diseases in various episodes, with medical experts providing clear explanations and insights.
Rare Disease Show Episode 19-- In today's show we will cover Pulmonary Arterial Hypertension.
Pulmonary Arterial Hypertension (PAH) is a rare but serious condition characterized by high blood pressure in the arteries that supply blood to the lungs.
This increased pressure strains the heart, specifically the right ventricle, as it works harder to pump blood through narrowed arteries. Over time, PAH can lead to symptoms such as shortness of breath, fatigue, chest pain, and, in advanced cases, right-sided heart failure.
Causes include genetic factors, connective tissue diseases, congenital heart defects, or it can be idiopathic. Treatment focuses on reducing symptoms, improving quality of life, and slowing disease progression through medications, oxygen therapy, or, in severe cases, surgery.
In this episode, Dr Brajesh Kumar Mishra, a cardiologist at Manipal Hospital, Gurgaon shares his insights by addressing questions asked by the Medical Dialogues team-
1. Can you explain what Pulmonary Arterial Hypertension (PAH) is and why is this a rare disease?
2. What are the primary causes or risk factors for PAH? Are there any emerging causes that we should be aware of?
3. How common is PAH, and who is most at risk for developing this condition?
4. What are the early symptoms of PAH, and how can patients differentiate them from other heart or lung conditions?
5. How is PAH diagnosed? What tests or procedures are typically used to confirm a diagnosis?
6. Can you describe the underlying pathophysiological mechanisms of PAH and how they lead to the development of symptoms?
7. What are the current mainstays of treatment for PAH, and how do they work to alleviate symptoms or slow disease progression?
8. Can you explain the role of pulmonary vasodilators in treating PAH?
9. What new or emerging therapies are showing promise in the treatment of PAH, and how do they compare to existing options?
10. What are the biggest challenges in managing PAH, both from a clinical and a patient perspective?
11. What are some of the most promising areas of research in PAH treatment? Are there any recent breakthroughs you find particularly exciting?
12. What do you think is the most critical factor in improving outcomes for patients with PAH?
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.